For example, in a therapeutic proof‐of‐principle experiment in the field of prostate cancer, we found that the SRPK1 inhibitors were able to inhibit phosphorylation of SR proteins and switch VEGF‐A splicing in vitro6. Here, SRPK1 is linked to Familial prostate cancer.